Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock

Investors looking to capitalize on the rapidly expanding weight loss drug market have increasingly more options. 63% ) and Novo Nordisk ( NVO -1.

Read the original report for the complete account of this story.